Bafna Pharmaceuticals exhibits inconsistent financial performance. While the company has demonstrated periods of growth, recent trends suggest a slowdown. The compounded sales growth over the past three years is 29%, but the TTM sales have declined by 10%. Similarly, the compounded profit growth over three years is 8%, but the TTM profit has significantly declined by 96%. This inconsistency in both sales and profit growth raises concerns about the sustainability of the company's financial performance. The quarterly sales and profit figures show considerable fluctuation, further highlighting the volatility in the company's earnings. The operating profit margin (OPM) has also been variable, with a recent decline to 4% in the TTM period.

Bafna Pharmaceuticals' capital efficiency and returns reflect a mixed performance. The ROCE stands at 9.56%, and the ROE is 9.52%. These figures indicate that the company is generating returns on its capital and equity, but the returns are not exceptionally high when compared to its peers. The cash conversion cycle shows variability, indicating potential inefficiencies in working capital management.

Bafna Pharmaceuticals has borrowings. The company has maintained a Dividend Payout % of 0% for the Latest year.

The shareholding pattern of Bafna Pharmaceuticals indicates strong promoter confidence, with 88.30% promoter holding as of December 2024. However, there has been a slight decrease in promoter holding from 90.42% in March 2022. A high promoter holding generally suggests that the company's management has a vested interest in its success.

The quarterly results of Bafna Pharmaceuticals show volatility in segment performance. Fluctuations in sales and profitability from quarter to quarter indicate potential instability in the company's revenue streams. For example, YOY Sales Growth % has varied significantly, ranging from -31.41% to 181.98%. Similarly, YOY Profit Growth % has fluctuated widely, from -198.00% to 806.58%. This variability indicates a need for more consistent and predictable financial performance.

Bafna Pharmaceuticals may have exposure to foreign exchange or interest rate risks. Fluctuations in exchange rates can impact the company's revenue and expenses, particularly if it operates internationally or has significant import/export activities. Changes in interest rates can affect the cost of borrowing and the company's profitability. Without specific data on these exposures, it is difficult to quantify the exact level of risk.